Results 131 to 140 of about 24,911 (203)

Retraction Note: Hypoxia impairs decitabine-induced expression of HLA-DR in acute myeloid leukaemia cell lines. [PDF]

Clin Epigenetics
Humphries S, Burnard SM, Eggins CD, Keely S, Bond DR, Lee HJ.   +5 more
europepmc   +1 more source

Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country. [PDF]

Leuk Res Rep
Nguyen HT, Bach QK, Nguyen QN, Nguyen VN, Nguyen TVA, Pham-The H.   +5 more
europepmc   +1 more source

Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series. [PDF]

Front Oncol
Li Q, Ji J, Wu Y.
europepmc   +1 more source

Prognostic value of BTG1 for predicting decitabine sensitivity in <i>de novo</i> acute myeloid leukemia. [PDF]

iScience
Zhang S, Li M, Xu B, Zhu X, Mao X, Zhou H, Tong X, Su S, Zhu Y, Zhang D.   +9 more
europepmc   +1 more source

Combining drugs that bypass p53 to treat TP53-mutated leukemias. [PDF]

Blood Adv
Biswas S, Zahran ZAM, Gu X, Cardone L, Marti R, Mouannes N, Stich M, Jain A, Fedorov K, Tomlinson B, Goldfinger M, Verma A, Saunthararajah Y.   +12 more
europepmc   +1 more source

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial. [PDF]

Cancers (Basel)
Handa S, Koenig K, Zhao Q, Mims AS, Vasu S, Garzon R, Haque T, Benson D, Klisovic RB, Marcucci G, Walker AR, Bhatnagar B.   +11 more
europepmc   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors. [PDF]

Int J Cancer
Wenger V, Garcia-Manero G, Zeiser R, Lübbert M.   +3 more
europepmc   +1 more source

Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression. [PDF]

Cell Oncol (Dordr)
Peng XM, Shi XP, Chen H, Cao LY, Zuo HJ, Guo JQ, Jiang N, Luo XY.   +7 more
europepmc   +1 more source

Decitabine-cedazuridine in patients with MDS and TP53 mutations. [PDF]

Blood Adv
Urrutia S, Sasaki K, Bataller A, Kantarjian H, Montalban-Bravo G, McCloskey J, Griffiths EA, Yee K, Zeidan A, Savona M, Oganesian A, Sano Y, Keer HN, Garcia-Manero G.   +13 more
europepmc   +1 more source

Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV-associated gastric cancer. [PDF]

mBio
Preston-Alp S, Wang Y, Bergonzoni M, Kossenkov A, Soldan SS, Caruso LB, Maestri D, Lieberman PM, Gewurz BE, Tempera I.   +9 more
europepmc   +1 more source